A new innovative mesothelioma clinical trial being conducted by the Swiss Group for Clinical Cancer Research is looking for patients. The clinical trial is trying to determine whether mesothelioma symptoms can be better controlled with or without the use of a newly developed electronic device. The Electronic Tool for Monitoring Symptoms and Syndromes Associated With Advanced Cancer (nicknamed E-MOSAIC) is a hand held tool used to record and monitor symptoms and assess the quality of life for patients with advanced cancer. Researchers hope the device will improve communication between patients and their doctors and improve their ability to plan treatments.

The E-MOSAIC trial is being conducted as a palliative treatment. Mesothelioma patients who participate in the trial will include persons with advanced incurable cancer looking to ease their pain and suffering rather than improve their prognosis. In order to participate, patients must be at least 18 years old and suffering from an advanced cancer that is causing pain, anorexia, weight loss, fatigue, depression, and/or anxiety. In addition, eligible patients must currently be receiving palliative anticancer treatment continuously every week, or every other week as an outpatient. Final eligibility will be determined by the health professionals conducting the E-MOSAIC trial.

Patients that are chosen to participate will be randomly assigned to one of two equal groups. In group one, patients will use a handheld electronic tool once a week to record information about their symptoms and diet. Nurses will record the patient’s weight and Karnofsky performance status once a week. In group two, patients will use a handheld electronic device once a week to rate specific symptoms including pain, fatigue, drowsiness, nausea and etc. Nurses will record the patient’s weight, Karnofsky performance status, body mass index, and use of medications for pain, anorexia, fatigue, or weight loss once a week.

For complete information regarding the study, click here